NONovo Nordisk A/S NONOF · OTC
$38.17 -1.74% (-$0.68)
- Market cap
- 1.15T kr
- Enterprise value
- 1.24T kr
- P/E
- 9.8x
- Forward P/E
- 11.8x
- PEG
- 9.3x
- P/S
- 3.5x
- P/FCF
- 15.1x
- EV/EBITDA
- 6.9x
- ROIC
- 29.7%
- Gross margin
- 80.7%
- Net margin
- 35.3%
- Dividend yield
- 4.63%
- Payout ratio
- 45.6%
- Net debt/EBITDA
- 0.5x
- Beta
- 0.35
- Free float
- 71.0%
About the company
Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark, primarily known for its innovative products and treatments for diabetes. Founded in 1923, the company has grown to become a leader in insulin products as well as medications for obesity and other chronic diseases, such as hemophilia and growth disorders. Novo Nordisk operates globally, distributing its products in over 170 countries worldwide.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Maziar Mike Doustdar
Employees
68,794
Headquarters
Bagsvaerd
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number